IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

10/799529

Confirmation No.:

8501

Applicant

Carl Podella

Filing Date

March 11, 2004

Title

ALTERING METABOLISM IN BIOLOGICAL PROCESSES

Group Art Unit :

1636

Examiner

Akhavan, Ramin

Docket No.

700145.4004

Customer No.

34313

Commissioner for Patents Mail Stop Amendment PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO/SB/08a (PTO-1449). In accordance with the USPTO waiver of the requirement under 37 CFR 1.98(a)(2)(i), only copies of foreign patent documents and non-patent literature are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

Applicant Appl. No. Examiner Docket No. Podella 10/799529 Akhavan, Ramin 700145.4004

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

\boxtimes	This ID	OS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b),
that is	(1) with	nin three months of the filing date of the application, which is not a continued
prosec	ution a	pplication filed under § 1.53(d); or (2) within three months of entry of the national
stage	as set f	orth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the
merits	or (4)	before the mailing of a first Office action after filing a request for continued
exami	nation ເ	under § 1.114. Thus, no fee is required.
		However, if the undersigned is in error in this regard, Applicant respectfully
		requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if
		applicable, and charge the fee due under 37 CFR §1.17(p) to the deposit
		account referenced below.
		However, if the undersigned is in error in this regard, Applicant respectfully
		requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if
		applicable, and a statement under 37 CFR § 1.97(e) is included below, thus
		no fee is required.
	This ID	OS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office
action	on the	merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance
under	37 CFF	R § 1.311.
		The fee due under 37 CFR § 1.17(p) is submitted herewith.
		A statement under 37 CFR § 1.97(e) is included below, thus no fee is
		required. In the event that this IDS is not received before a Final Action or a
		Notice of Allowance, then Applicant respectfully requests that the Office
		consider the filing of these papers to be submitted under 37 CFR § 1.97(d)
		and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.
	This IE	OS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37
CFR §	1.113	or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue
fee. A	statem	nent under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR
§ 1.17	(p) is sı	ubmitted herewith.

Applicant Appl. No. Examiner

Podella 10/799529

Docket No.

Akhavan, Ramin 700145.4004

_	STATEMENT UNDER 37 CFR § 1.97(e):				
	Each item contained in this IDS was first cited in any communication from a foreign				
patent	office in a counterpart foreign application not more than three months prior to the filing of				
this ID	S.				
	No item contained in this IDS was cited in a communication from a foreign patent office				
in a co	ounterpart foreign application, and, to the knowledge of the person signing this statement				
after m	naking reasonable inquiry, no item of information contained in this IDS was known to any				
individ	ual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.				
	PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:				
	A check in the amount of is enclosed for the above fee(s).				
	Please charge to Deposit Account No. 15-0665 for the above fee(s).				
\boxtimes	The Commissioner is authorized to charge any fees required by the filing of these				
papers, and to credit any overpayment to Orrick, Herrington & Sutcliffe's Deposit Account					
No. 15-0665 .					
	Respectfully submitted,				
	ORRICK, HERRINGTON & SUTCHEFE LLP				
Dated	: June 8, 2006 By: Charles C. Fowler				
	Reg. No. 39,675				

ORRICK, HERRINGTON & SUTCLIFFE LLP 4 Park Plaza, Suite 1600 Irvine, CA 92614 949/567-6700 Telephone 949/567-6710 Facsimile

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent And Trade

	Under the Paperwork Reduction Act of 1995, no persons are requirem 1449A/PTO			uired to respond to a collection of information unless it contains a valid OMB control number Complete if Known		
				Application Number	10/799529	
	IFORMATION DISCLOSURE			Filing Date	March 11, 2004	
	TATEMENT I	BY APPLICAN	NT	First Named Inventor	Podella	
				Art Unit	1636	
	(use as many sheets as necessary)			Examiner Name	Akhavan, Ramin	
Sheet	1	of	1	Attorney Docket Number	700145.4004	

		U.S. PA	TENT DOCUMENTS		
Examiner		U.S. Patent Document	Publication Date	. Name of Patentee or	
Initials	Cite No.1	Number-Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	
/N.V./	AA	2,320,479	6/19/1939	Sperti	
8	AB	3,404,068	10/1/1968	Battistoni	
-	AC	3,635,797	1/18/1972	Battistoni, et al.	
	AD	5,238,925	8/24/1993	Bentley	
	AE	5,356,874	10/18/1994	Bentley	
	AF	5,514,591	5/7/1996	Levin	
	AG	5,714,169	2/3/1998	Levin	
-	AH	5,820,758	10/13/1998	Dale, et al.	
	Al	5,849,566	12/15/1998	Dale, et al.	
900	AJ	5,885,950	3/23/1999	Dale, et al.	
	AK	5,897,928	4/27/1999	Sanders, et al.	
$\neg \forall$	AL	6,033,875	3/7/2000	Bussineau, et al.	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Cite No.1	item (book magazine journal serial symposium catalog etc.) date page(s) volume-issue number(s).	Τ²		
BA	"Baker's Yeast Production" (Chap. 6, Pages 261-313) 1991			
BB	William D. Pandolfe, Ph.D., "Cell Disruption by Homogenization"			
ВС	Donna J. Schlemm, et al. "Medicinal Yeast Extracts" Cell Stress and enaperones (February 1999, 4 (3), Pages 171-176)			
BD	Healing" Arch Surg (May, 1009, Vol. 124, Pages 641-646) (1990)			
BE	Euan W. Low, et al. "Reducing Production of Excess Biomass During Wastewater Treatment" Wat. Res., (Vol. 33, No. 5, pp. 1119-1132, 1999)			
BF	Euan W. Low, et al. "The Use of Chemical Uncouplers for Reducing Biomass Production During Biodegradation" Wat. Sci. Tech. (Vol. 37, No. 4-5, pp. 399-402, 1998)			
BG	James B. Russell, et al. "Energetics of Bacterial Growth: Balance of Anabolic and Catabolic Reactions" Microbiological Reviews (March, 1995, pp. 48-62)			
	BA BB BC BD BE BF	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. BA "Baker's Yeast Production" (Chap. 6, Pages 261-313) 1991 BB William D. Pandolfe, Ph.D., "Cell Disruption by Homogenization" BC Donna J. Schlemm, et al. "Medicinal Yeast Extracts" Cell Stress and Chaperones (February 1999, 4 (3), Pages 171-176) BD J. Peter Bentley, Ph.D., et al. "Peptides From Live Yeast Cell Derivative Stimulate Wound Healing" Arch Surg (May, 1009, Vol. 124, Pages 641-646) (1990) BE Euan W. Low, et al. "Reducing Production of Excess Biomass During Wastewater Treatment" Wat. Res., (Vol. 33, No. 5, pp. 1119-1132, 1999) BF Euan W. Low, et al. "The Use of Chemical Uncouplers for Reducing Biomass Production During Biodegradation" Wat. Sci. Tech. (Vol. 37, No. 4-5, pp. 399-402, 1998) BG James B. Russell, et al. "Energetics of Bacterial Growth: Balance of Anabolic and Catabolic		

Examiner	/Nancy Vogel/	Date	04/09/2007
Signature	/Nancy Vogel/	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicants unique citation designation number (optional). ²See Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is govern by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450